

Hepatitis B Vaccine Market Report and Forecast 2024-2032

Market Report | 2023-10-01 | 160 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2999.00
- Five User License \$3999.00
- Corporate License \$5999.00

Report description:

Hepatitis B Vaccine Market Report and Forecast 2024-2032

Hepatitis B Vaccine Market Outlook

The hepatitis b vaccine market size was valued at USD 4.8 billion in 2023, driven by a combination of factors. The market size is anticipated to grow at a CAGR of 4.8% during the forecast period of 2024-2032 to achieve a value of USD 7.3 billion by 2032.

Hepatitis B Vaccine: Introduction

The Hepatitis B vaccine is a vital immunization tool designed to prevent Hepatitis B; a potentially life-threatening liver infection caused by the Hepatitis B virus (HBV). This vaccine provides immunity by introducing a small part of the virus's outer surface into the body, prompting the immune system to develop antibodies without causing the disease itself. Hepatitis B can lead to severe health issues, including cirrhosis, liver cancer, and even death.

The vaccine's introduction has been a major medical breakthrough, significantly reducing the number of new infections and providing protection for a lifetime when administered in a full series. It is typically given in multiple doses, starting from birth in many countries, and is considered one of the most effective ways to prevent the spread of this contagious disease. The widespread adoption of the Hepatitis B vaccine has played a pivotal role in the global fight against liver-related illnesses and has been instrumental in safeguarding countless individuals from the complications of HBV.

Key Trends in the Hepatitis B Vaccine Market

The Hepatitis B vaccine market has experienced several notable trends driven by various factors. Firstly, there's an increased emphasis on government-led immunization programs, especially in countries with a high prevalence of Hepatitis B infections. Many governments have incorporated Hepatitis B vaccination into their national immunization schedules, starting from birth or early childhood, to ensure widespread coverage. Another trend is the ongoing research and development aimed at enhancing

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

vaccine efficacy and duration of immunity. This includes efforts to create combination vaccines that can protect against multiple diseases with fewer shots. The rise in travel and migration has also spurred demand for the vaccine, as individuals move to or visit areas endemic with the virus.

Moreover, public awareness campaigns have gained momentum, highlighting the importance of vaccination and its role in preventing potential complications of Hepatitis B like liver cirrhosis or cancer. However, the market faces challenges too, including supply constraints and the need for cold storage, which can limit vaccine accessibility in certain regions. In essence, the Hepatitis B vaccine market is shaped by a blend of public health initiatives, scientific advancements, and socio-economic factors, all converging to combat a major liver-related threat.

Hepatitis B Vaccine Market Segmentation

Market Breakup by Type

- Single Antigen
- Combination

Market Breakup by Age

- Pediatrics
- Adults

Market Breakup by End User

- Hospitals
- Clinics
- Vaccination Centres
- Others

Market Breakup by Region

- United States
- EU-4 and the United Kingdom
 - o□Germany
 - o□France
 - o□Italy
 - o□Spain
 - o□United Kingdom
- Japan

Hepatitis B Vaccine Market Overview

The Hepatitis B vaccine market is a significant segment within the broader pharmaceutical landscape, underscored by the critical need to prevent Hepatitis B—a serious liver infection that can lead to severe complications like cirrhosis and liver cancer. The market's growth has been driven by a combination of factors. Government initiatives and health organizations have stressed the importance of immunization, leading to the inclusion of the Hepatitis B vaccine in national immunization programs across many countries. This widespread adoption, especially in regions with a high prevalence of the disease, has led to increased vaccine demand. Additionally, the market has benefited from consistent R&D efforts, leading to innovations like combination vaccines and enhanced formulations.

Challenges such as vaccine accessibility in remote regions, pricing issues in some markets, and occasional supply chain

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

bottlenecks have occasionally hindered the market's growth. However, collaborations between governments, international organizations, and vaccine manufacturers aim to address these challenges and ensure broader vaccine distribution. In essence, the Hepatitis B vaccine market is characterized by its central role in public health efforts, continuous innovation, and the collective drive to achieve worldwide immunization against this dangerous disease.

Hepatitis B Vaccine Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- Merck & Co., Inc.
- Sanofi S.A.
- Dynavax Technologies Corporation
- GlaxoSmithKline plc.
- Pancea Biotech Ltd
- Beijing Tiantan Biological Products Co., Ltd.
- VBI Vaccines Inc.
- Emmy Vaccine Co., Ltd.
- Beijing Minhai Biological Technology Co., Ltd.

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Hepatitis B Disease Overview
 - 3.1 Guidelines and Stages
 - 3.2 Pathophysiology
 - 3.3 Screening and Diagnosis
 - 3.4 Treatment Pathway
- 4 Patient Profile
 - 4.1 Patient Profile Overview
 - 4.2 Patient Psychology and Emotional Impact Factors
 - 4.3 Risk Assessment and Treatment Success Rate
- 5 Hepatitis B Disease Epidemiology Analysis - 7MM
 - 5.1 7MM Epidemiology Scenario Overview (2017-2032)
 - 5.2 United States Hepatitis B Disease Epidemiology Forecast (2017-2032)
 - 5.3 EU-4 and United Kingdom Hepatitis B Disease Epidemiology Forecast (2017-2032)
 - 5.3.1 Germany Hepatitis B Disease Epidemiology Forecast (2017-2032)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.3.2 France Hepatitis B Disease Epidemiology Forecast (2017-2032)
- 5.3.3 Italy Hepatitis B Disease Epidemiology Forecast (2017-2032)
- 5.3.4 Spain Hepatitis B Disease Epidemiology Forecast (2017-2032)
- 5.3.5 United Kingdom Hepatitis B Disease Epidemiology Forecast (2017-2032)
- 5.4 Japan Hepatitis B Disease Epidemiology Forecast (2017-2032)
- 6 Hepatitis B Vaccine Market Overview - 7MM
 - 6.1 Hepatitis B Vaccine Market Historical Value (2017-2023)
 - 6.2 Hepatitis B Vaccine Market Forecast Value (2024-2032)
- 7 Hepatitis B Vaccine Market Landscape - 7MM
 - 7.1 Hepatitis B Vaccine: Developers Landscape
 - 7.1.1 Analysis by Year of Establishment
 - 7.1.2 Analysis by Company Size
 - 7.1.3 Analysis by Region
 - 7.2 Hepatitis B Vaccine: Product Landscape
 - 7.2.1 Analysis by Type
 - 7.2.2 Analysis by Treatment Type
 - 7.2.3 Analysis by Diagnosis Method
- 8 Hepatitis B Vaccine Challenges and Unmet Needs
 - 8.1 Treatment Pathway Challenges
 - 8.2 Compliance and Drop-Out Analysis
 - 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Hepatitis B Vaccine Market Dynamics
 - 10.1 Market Drivers and Constraints
 - 10.2 SWOT Analysis
 - 10.3 Porter's Five Forces Model
 - 10.4 Key Demand Indicators
 - 10.5 Key Price Indicators
 - 10.6 Industry Events, Initiatives, and Trends
 - 10.7 Value Chain Analysis
- 11 Hepatitis B Vaccine Market Segmentation - 7MM
 - 11.1 Hepatitis B Vaccine Market by Type
 - 11.1.1 Market Overview
 - 11.1.2 Single Antigen
 - 11.1.3 Combination
 - 11.2 Hepatitis B Vaccine Market by Age
 - 11.2.1 Market Overview
 - 11.2.2 Pediatrics
 - 11.2.3 Adults
 - 11.3 Hepatitis B Vaccine Market by End User
 - 11.3.1 Market Overview
 - 11.3.2 Hospitals
 - 11.3.3 Clinics
 - 11.3.4 Vaccination Centres
 - 11.3.5 Others
 - 11.4 Hepatitis B Vaccine Market by Region
 - 11.4.1 Market Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.4.2 United States
- 11.4.3 EU-4 and the United Kingdom
 - 11.4.3.1 Germany
 - 11.4.3.2 France
 - 11.4.3.3 Italy
 - 11.4.3.4 Spain
 - 11.4.3.5 United Kingdom
- 11.4.4 Japan
- 12 United States Hepatitis B Vaccine Market
 - 12.1 Hepatitis B Vaccine Market Historical Value (2017-2023)
 - 12.2 Hepatitis B Vaccine Market Forecast Value (2024-2032)
 - 12.3 Hepatitis B Vaccine Market by Type
 - 12.4 Hepatitis B Vaccine Market by Treatment Type
- 13 EU-4 and United Kingdom Hepatitis B Vaccine Market
 - 13.1 Hepatitis B Vaccine Market Historical Value (2017-2023)
 - 13.2 Hepatitis B Vaccine Market Forecast Value (2024-2032)
 - 13.3 Germany Hepatitis B Vaccine Market Overview
 - 13.3.1 Hepatitis B Vaccine Market by Type
 - 13.3.2 Hepatitis B Vaccine Market by Treatment Type
 - 13.4 France Hepatitis B Vaccine Market Overview
 - 13.4.1 Hepatitis B Vaccine Market by Type
 - 13.4.2 Hepatitis B Vaccine Market by Treatment Type
 - 13.5 Italy Hepatitis B Vaccine Market Overview
 - 13.5.1 Hepatitis B Vaccine Market by Type
 - 13.5.2 Hepatitis B Vaccine Market by Treatment Type
 - 13.6 Spain Hepatitis B Vaccine Market Overview
 - 13.6.1 Hepatitis B Vaccine Market by Type
 - 13.6.2 Hepatitis B Vaccine Market by Treatment Type
 - 13.7 United Kingdom Hepatitis B Vaccine Market Overview
 - 13.7.1 Hepatitis B Vaccine Market by Type
 - 13.7.2 Hepatitis B Vaccine Market by Treatment Type
- 14 Japan Hepatitis B Vaccine Market
 - 14.1 Hepatitis B Vaccine Market Historical Value (2017-2023)
 - 14.2 Hepatitis B Vaccine Market Forecast Value (2024-2032)
 - 14.3 Hepatitis B Vaccine Market by Type
 - 14.4 Hepatitis B Vaccine Market by Treatment Type
- 15 Regulatory Framework
 - 15.1 Regulatory Overview
 - 15.1.1 US FDA
 - 15.1.2 EU EMA
 - 15.1.3 INDIA CDSCO
 - 15.1.4 JAPAN PMDA
 - 15.1.5 Others
- 16 Clinical Trials Analysis
 - 16.1 Analysis by Trial Registration Year
 - 16.2 Analysis by Trial Status
 - 16.3 Analysis by Trial Phase

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.4 Analysis by Therapeutic Area
- 16.5 Analysis by Geography
- 17 Funding and Investment Analysis
 - 17.1 Analysis by Funding Instances
 - 17.2 Analysis by Type of Funding
 - 17.3 Analysis by Funding Amount
 - 17.4 Analysis by Leading Players
 - 17.5 Analysis by Leading Investors
 - 17.6 Analysis by Geography
- 18 Partnership and Collaborations Analysis
 - 18.1 Analysis by Partnership Instances
 - 18.2 Analysis by Type of Partnership
 - 18.3 Analysis by Leading Players
 - 18.4 Analysis by Geography
- 19 Supplier Landscape
 - 19.1 Merck & Co.,Inc.
 - 19.1.1 Financial Analysis
 - 19.1.2 Product Portfolio
 - 19.1.3 Demographic Reach and Achievements
 - 19.1.4 Mergers and Acquisitions
 - 19.1.5 Certifications
 - 19.2 Sanofi S.A.
 - 19.2.1 Financial Analysis
 - 19.2.2 Product Portfolio
 - 19.2.3 Demographic Reach and Achievements
 - 19.2.4 Mergers and Acquisitions
 - 19.2.5 Certifications
 - 19.3 Dynavax Technologies Corporation
 - 19.3.1 Financial Analysis
 - 19.3.2 Product Portfolio
 - 19.3.3 Demographic Reach and Achievements
 - 19.3.4 Mergers and Acquisitions
 - 19.3.5 Certifications
 - 19.4 GlaxoSmithKline plc.
 - 19.4.1 Financial Analysis
 - 19.4.2 Product Portfolio
 - 19.4.3 Demographic Reach and Achievements
 - 19.4.4 Mergers and Acquisitions
 - 19.4.5 Certifications
 - 19.5 Pancea Biotech Ltd
 - 19.5.1 Financial Analysis
 - 19.5.2 Product Portfolio
 - 19.5.3 Demographic Reach and Achievements
 - 19.5.4 Mergers and Acquisitions
 - 19.5.5 Certifications
 - 19.6 Beijing Tiantan Biological Products Co., Ltd.
 - 19.6.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 19.6.2 Product Portfolio
- 19.6.3 Demographic Reach and Achievements
- 19.6.4 Mergers and Acquisitions
- 19.6.5 Certifications
- 19.7 VBI Vaccines Inc.
 - 19.7.1 Financial Analysis
 - 19.7.2 Product Portfolio
 - 19.7.3 Demographic Reach and Achievements
 - 19.7.4 Mergers and Acquisitions
 - 19.7.5 Certifications
- 19.8 Emmy Vaccine Co.,Ltd.
 - 19.8.1 Financial Analysis
 - 19.8.2 Product Portfolio
 - 19.8.3 Demographic Reach and Achievements
 - 19.8.4 Mergers and Acquisitions
 - 19.8.5 Certifications
- 19.9 Beijing Minhai Biological Technology Co., Ltd.
 - 19.9.1 Financial Analysis
 - 19.9.2 Product Portfolio
 - 19.9.3 Demographic Reach and Achievements
 - 19.9.4 Mergers and Acquisitions
 - 19.9.5 Certifications
- 20 Hepatitis B Vaccine - Distribution Model (Additional Insight)
 - 20.1 Overview
 - 20.2 Potential Distributors
 - 20.3 Key Parameters for Distribution Partner Assessment
- 21 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 22 Company Competitiveness Analysis (Additional Insight)
 - 22.1 Very Small Companies
 - 22.2 Small Companies
 - 22.3 Mid-Sized Companies
 - 22.4 Large Companies
 - 22.5 Very Large Companies
- 23 Payment Methods (Additional Insight)
 - 23.1 Government Funded
 - 23.2 Private Insurance
 - 23.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Hepatitis B Vaccine Market Report and Forecast 2024-2032

Market Report | 2023-10-01 | 160 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$2999.00
	Five User License	\$3999.00
	Corporate License	\$5999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com